A PHASE Ib STUDY OF CRLX101 IN COMBINATION WITH WEEKLY PACLITAXEL IN PATIENTS WITH RECURRENT OR PERSISTENT EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER

Trial Profile

A PHASE Ib STUDY OF CRLX101 IN COMBINATION WITH WEEKLY PACLITAXEL IN PATIENTS WITH RECURRENT OR PERSISTENT EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 24 Apr 2017

At a glance

  • Drugs Camptothecin (Primary) ; Paclitaxel
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Adverse reactions
  • Sponsors Cerulean Pharma; New Links Genetics Corporation
  • Most Recent Events

    • 30 Jan 2017 Status changed from recruiting to active, no longer recruiting.
    • 03 Nov 2016 According to a Cerulean Pharma media release, results from this trial expected during 2017.
    • 11 Oct 2016 Results (n=9; as of 11 Mar 2016) presented at the 41st European Society for Medical Oncology Congress
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top